Connect Biopharma Holdings Ltd
CNTB1.570USD
-0.040-2.48%
收盘 09/19, 16:00（美东）报价延迟15分钟
87.26M总市值
亏损市盈率 TTM
关于 Connect Biopharma Holdings Ltd 公司
Connect Biopharma Holdings Limited 是一家全球临床阶段生物制药公司，专注于通过开发源自 T 细胞驱动研究的疗法来改善慢性炎症疾病患者的生活。该公司正在建立专有小分子和抗体产品线，使用功能性 T 细胞检测来筛选和发现针对经过验证的免疫靶点的有效候选产品。其主要候选产品 rademikibart 是一种针对白细胞介素 4 受体 α (IL-4Rα) 的抗体，正在开发用于治疗特应性皮炎 (AD) 和哮喘。作为 IL-4Rα 的抑制剂，rademikibart 可阻断 IL-4 和 IL-13 的炎症信号传导。其第二个候选产品 icanbelimod 是 S1P1 T 细胞受体的调节剂，正在开发用于治疗溃疡性结肠炎 (UC)。Icanbelimod 是一种口服的 S1P1 小分子调节剂，旨在减少炎症而不杀死 T 细胞。
公司简介
公司代码CNTB
公司名称Connect Biopharma Holdings Ltd
上市日期Mar 19, 2021
CEODr. Barry D. Quart, Pharm.D.
员工数量62
证券类型Ordinary Share
年结日Mar 19
公司地址3580 Carmel Mountain Road, Suite 200
城市SAN DIEGO
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编92130
电话18587271040
网址https://www.connectbiopharm.com
公司代码CNTB
上市日期Mar 19, 2021
CEODr. Barry D. Quart, Pharm.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
131.89K
--
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
80.00K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
10.00K
--
Ms. Lisa Peraza
Ms. Lisa Peraza
Vice President - Finance
Vice President - Finance
--
--
Kimberly Kimberly
Kimberly Kimberly
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Dr. Lei Sun, Ph.D.
Dr. Lei Sun, Ph.D.
Vice President - Biologics and Head of CMC
Vice President - Biologics and Head of CMC
--
--
Mr. Jeff Cohn, J.D.
Mr. Jeff Cohn, J.D.
General Counsel and Corporate Secretary
General Counsel and Corporate Secretary
--
--
Mr. Raul Collazo, Ph.D.
Mr. Raul Collazo, Ph.D.
Vice President - Global Medical Affairs
Vice President - Global Medical Affairs
--
--
Mr. David L. Szekeres
Mr. David L. Szekeres
President
President
--
--
Dr. Kan Chen, Ph.D.
Dr. Kan Chen, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
131.89K
--
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
80.00K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
10.00K
--
Ms. Lisa Peraza
Ms. Lisa Peraza
Vice President - Finance
Vice President - Finance
--
--
Kimberly Kimberly
Kimberly Kimberly
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Dr. Lei Sun, Ph.D.
Dr. Lei Sun, Ph.D.
Vice President - Biologics and Head of CMC
Vice President - Biologics and Head of CMC
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
Panacea Venture
25.04%
BioFortune Inc
11.05%
Wei (Zheng)
10.64%
Shanghai Minhui Enterprise Management Consulting Partnership
9.52%
Qiming Venture Partners
8.69%
其他
35.06%
持股股东
持股股东
占比
Panacea Venture
25.04%
BioFortune Inc
11.05%
Wei (Zheng)
10.64%
Shanghai Minhui Enterprise Management Consulting Partnership
9.52%
Qiming Venture Partners
8.69%
其他
35.06%
股东类型
持股股东
占比
Venture Capital
39.76%
Corporation
29.12%
Individual Investor
11.41%
Investment Advisor
4.05%
Hedge Fund
0.39%
Investment Advisor/Hedge Fund
0.04%
其他
15.22%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
50
47.05M
84.81%
-3.22M
2025Q1
52
47.02M
84.62%
-3.27M
2024Q4
55
47.53M
86.01%
-3.17M
2024Q3
62
47.29M
85.59%
-4.20M
2024Q2
69
47.32M
85.65%
-6.58M
2024Q1
72
46.88M
84.93%
-2.00M
2023Q4
79
44.04M
79.91%
+3.48M
2023Q3
88
43.03M
78.17%
-1.22M
2023Q2
89
43.32M
78.69%
-1.54M
2023Q1
102
43.88M
79.72%
-2.14M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Panacea Venture
13.41M
24.14%
+1.41M
+11.75%
Jun 28, 2024
BioFortune Inc
6.16M
11.08%
--
--
Mar 21, 2025
Wei (Zheng)
5.93M
10.67%
--
--
Mar 21, 2025
Shanghai Minhui Enterprise Management Consulting Partnership
5.31M
9.55%
--
--
Mar 21, 2025
Qiming Venture Partners
4.84M
8.71%
--
--
Mar 21, 2025
Advantech Capital II L.P.
4.76M
8.57%
--
--
Mar 21, 2025
Lilly Asia Ventures
3.34M
6.01%
--
--
Mar 21, 2025
BML Capital Management LLC
2.09M
3.77%
--
--
Mar 31, 2025
Szekeres (David Leslie)
160.87K
0.29%
+160.87K
--
Mar 21, 2025
Choreo, LLC
160.87K
0.29%
--
--
Mar 31, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
